Search Results

Bio NC

ProKidney to Participate in the 2024 Jefferies Global Healthcare Conference

ProKidney Corp. announced that senior members of the management team will be participating in the Jefferies Global Healthcare Conference taking place from June 4 – 6, 2024 in New York, NY.

May 29, 2024

·

1 min read

Bio NC

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Corp. announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses.

June 10, 2024

·

5 min read

Drug Development

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

ProKidney Corp. announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company’s renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical and operational updates.

June 10, 2024

·

7 min read

Business

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

March 21, 2024

·

14 min read

Bio NC

ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that it has closed its SEC-registered underwritten public offering and concurrent registered direct offering.

June 17, 2024

·

4 min read

Bio NC

ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering

ProKidney Corp. announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions.

June 11, 2024

·

5 min read

Press Releases

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

·

1 min read

Business

ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

August 9, 2024

·

11 min read

Business

ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations

ProKidney Corp. announced two recent strategic appointments enhancing the leadership team’s expertise in clinical operations and technical operations, positioning the Company for completion of its Phase 3 program and future commercialization.

March 25, 2024

·

6 min read

Bio NC

ProKidney to Participate in Jefferies Biotech on the Bay Summit - February 29, 2024

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024.

February 29, 2024

·

1 min read